RK-251: What we know about India’s new ‘smart’ cancer drug that ‘could replace chemotherapy’
India’s researchers have developed an experimental cancer drug called RK-251 that could potentially replace traditional chemotherapy in the future. This "smart" drug is designed to remain inactive until it reaches cancer cells, which typically have higher levels of reactive oxygen species (ROS). When RK-251 encounters cancer cells, the ROS trigger its activation, releasing an anticancer compound that targets proteins essential for cancer cell survival. This approach could lead to more selective cancer treatment, reducing damage to healthy cells.
In preclinical studies, RK-251 demonstrated strong activity against aggressive triple-negative breast cancer cells with minimal effects on healthy cells. Studies in zebrafish embryos also showed no obvious signs of toxicity, suggesting the drug's ROS-responsive activation mechanism may be safe for further research. However, these findings are not yet definitive, and extensive human studies are needed to establish safety, appropriate dosing, and efficacy in humans.
While RK-251 could potentially become another valuable option in cancer treatment, it is unlikely to completely replace chemotherapy.
Written by urgent.news from The Indian Express's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
